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A B S T R A C T
There is growing interest in non-invasive brain stimulation (NIBS) as a novel treatment option for substance-use
disorders (SUDs). Recent momentum stems from a foundation of preclinical neuroscience demonstrating links
between neural circuits and drug consuming behavior, as well as recent FDA-approval of NIBS treatments for
mental health disorders that share overlapping pathology with SUDs. As with any emerging field, enthusiasm
must be tempered by reason; lessons learned from the past should be prudently applied to future therapies. Here,
an international ensemble of experts provides an overview of the state of transcranial-electrical (tES) and
transcranial-magnetic (TMS) stimulation applied in SUDs. This consensus paper provides a systematic literature
review on published data – emphasizing the heterogeneity of methods and outcome measures while suggesting
strategies to help bridge knowledge gaps. The goal of this effort is to provide the community with guidelines for
best practices in tES/TMS SUD research. We hope this will accelerate the speed at which the community
translates basic neuroscience into advanced neuromodulation tools for clinical practice in addiction medicine.
1. Introduction
Human neuroimaging and preclinical investigations have advanced
our knowledge of the neural circuitry that perpetuates the cycle of re-
lapse and recovery in substance use disorders (SUD). The challenge now
is to translate this knowledge into evidence-based interventions for
patients with SUDs (Ekhtiari and Paulus, 2016). Two tools that de-
monstrate promise in bridging this gap are transcranial electrical sti-
mulation (tES) and transcranial magnetic stimulation (TMS) (Fig. 1)
(Coles et al., 2018; Hone-Blanchet et al., 2015; Yavari et al., 2016).
While these non-invasive brain stimulation (NIBS) techniques are still
in an early stage of development for SUDs, there is a growing inter-
national community of investigators who are attempting to optimize,
evaluate, and validate their use as novel treatments for individuals
seeking treatment for SUDs. Three meta-analyses show preliminary but
promising results with tES/TMS in addiction medicine (Jansen et al.,
2013; Maiti et al., 2017; Slotema et al., 2010). While, other non-elec-
tromagnetic technologies for NIBS, such as ultrasound and near infrared
light, may offer benefits in the future, they are less well developed and
have not been studied for SUDs at present, and therefore are not in-
cluded in this review.
The purpose of this consensus paper is to review the current body of
knowledge of the utility of NIBS for SUDs and our current under-
standing of the biological basis through which these techniques mod-
ulate the brain. An important challenge has been the tremendous
variability in the methods and outcome measures across tES/TMS trials
in SUDs. Additionally, as with most innovative approaches, many (al-
though not all) of the NIBS studies published in the SUD field have
small sample sizes, do not contain rigorous control conditions, and are
not sufficiently blinded. This makes reproducibility and interpretation
difficult.
To address these limitations and to propose a new framework for
future research, we have assembled an international collaborative
group of investigators with expertise in neuromodulation and addiction
research (international network of tES/TMS trials for addiction medi-
cine (INTAM)). We had three webinars (September 2018, January
2019, and April 2019; recorded videos of the webinars are available on
YouTube), and two joint meetings in parallel to the New York city
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neuromodulation meeting (August 2018) and 3rd international brain
stimulation conference in Vancouver (February 2019). We review the
literature, discuss current gaps in our knowledge, and provide strategies
aimed at bridging these gaps. This consensus paper proposes guidelines
for best practices in tES/TMS SUD research. Our hope is that this will
accelerate the speed with which we can work together as a community
to translate basic neuroscience findings into advanced neuromodulation
tools for clinical practice.
2. General methodological parameter space in tES/TMS
2.1. TMS technical specifications
Transcranial magnetic stimulation is based on the electromagnetic
induction principle where brief focal electromagnetic pulses penetrate
the skull to stimulate target brain regions. The magnetic field is usually
strong enough to induce firing of neurons beneath the area where the
coil is positioned over the scalp. TMS pulses can be applied as single
pulses (spTMS), as two paired-pulses (PP-TMS), or as repetitive trains of
stimulation that may be either continuous at a specific frequency (re-
petitive- or rTMS), or patterned with specific inter-train intervals (e.g.
either intermittent or continuous theta-burst stimulation, iTBS/cTBS).
Both sp- and PP-TMS can be used to measure cortical excitability; rTMS
and TBS have been shown to induce changes and after-effects in cortical
excitability (section 2c). For all applications of TMS, and indeed for all
types of NIBS, stimulation frequency, pattern of stimulation, and the
intensity of the stimulation are crucial parameters. These factors affect
the magnitude of the delivered electric field and activation of neuronal
populations relative to the cortical gyri surface. Equally critical are
safety parameters and ensuring stimulation tolerability of the stimula-
tion. For most applications, stimulation intensity may be set as a per-
centage of an individual's threshold for inducing an electromyographic
motor evoked potential (MEP) of a peripheral muscle (Rossi et al.,
2009).
2.2. tES technical specifications
In contrast to TMS, transcranial electrical stimulation (tES) involves
delivering low-intensity electric currents through electrodes placed on
the scalp and/or upper body. The two most common stimulation
paradigms are transcranial direct current stimulation (tDCS) and tran-
scranial alternating current stimulation (tACS). Depending on the tar-
geted area(s) of stimulation, carbon rubber or silver chloride electrodes
covered in a conductive liquid or gel are placed over the scalp, with
lead wires connecting to a battery powered constant-current stimulator
that delivers currents in the milli-ampere ranges. Conventional doses,
with stimulation intensities up to 2mA, and durations of up to 30min,
are considered safe as measured by behavioral outcomes and neuroi-
maging, in both humans and in animals (Bikson et al., 2016). In con-
trast to TMS, tDCS does not directly induce neuronal firing, but is
thought to modulate cortical excitability by a polarity-dependent shift
of the neuronal membrane potential (Bindman et al., 1964; Nitsche and
Paulus, 2000; Nitsche and Paulus, 2001). The directionality of mem-
brane polarization is determined by the electrical field orientation re-
lative to neuronal orientation (Kabakov et al., 2012; Rawji et al., 2018);
(Woods et al., 2016a). In this sense, “anodal” or “cathodal” tDCS should
be understood as indicative of placement of the anode or cathode
electrodes over a target region (Woods et al., 2016a). “High-definition”
tES, using arrays of multiple smaller electrodes, may provide more focal
stimulation (Datta et al., 2009; Edwards et al., 2013). On the macro-
scopic level, placement of the anode over the motor cortex enhances
excitability, while placement of the cathode over the motor cortex re-
duces cortical excitability (Bindman et al., 1964; Nitsche and Paulus,
2000; Nitsche and Paulus, 2001). tACS is based on the delivery of an
alternating current with a sinusoidal or other patterned waveform
(Antal et al., 2008) to modulate the power and/or phase of endogenous
brain oscillations through entrainment (Ali et al., 2013; Reato et al.,
2013). Both the frequency and relative phase are critical parameters in
tACS experiments (Giordano et al., 2017; Kutchko and Frohlich, 2013;
Yavari et al., 2018).
2.3. tES/TMS mechanisms and dependent factors
Considerable insights into the mechanism of tES/TMS have been
provided by human neuroimaging and electromyographic (EMG) stu-
dies that measure motor excitability after brain stimulation. High-fre-
quency rTMS (>5Hz) facilitates, while low-frequency rTMS (<1Hz)
inhibits motor cortical excitability (Pascual-Leone et al., 1994). Like-
wise, iTBS and cTBS were shown to facilitate and reduce motor cortical
excitability, respectively, but with a shorter stimulation duration
compared to rTMS (Cárdenas-Morales et al., 2010; Huang et al., 2005).
Anodal tDCS at a 1mA intensity applied for 13min over the motor
cortex was shown to enhance cortical excitability, while cathodal tDCS
applied for 9min reduced excitability, both effects lasting for up to 1 h
after stimulation (Nitsche and Paulus, 2001; Nitsche et al., 2003c). The
primary hypothesized mechanism underlying the neuromodulatory ef-
fects of these techniques is long-term potentiation (LTP)- or long-term
depression (LTD)-like change in the synaptic coupling of neurons (see
reviews by Chervyakov et al., 2015; Stagg and Nitsche, 2011). Direc-
tionality of LTP or LTD is dependent on the frequency (for TMS), in-
tensity and duration of the stimulation. A rapid post-synaptic increase
in calcium ions can induce LTP, which has been noted with high
Fig. 1. Three major non-invasive brain stimu-
lation technologies. Repeated transcranial
magnetic stimulation (rTMS) in its both con-
ventional and deep forms and also transcranial
direct current stimulation (tDCS) have been
used frequently in addiction medicine trials.
Other forms of the transcranial electrical sti-
mulation (tES), like transcranial alternating
current stimulation (tACS) have not been used
in published addiction medicine trials (till
June 1, 2018).
H. Ekhtiari, et al. Neuroscience and Biobehavioral Reviews 104 (2019) 118–140
120
frequency (10 Hz) rTMS, iTBS, or anodal tDCS, whereas a slower and
sustained flux of calcium ions induces LTD after 1 Hz rTMS, cTBS, and
cathodal tDCS (Cirillo et al., 2017; Huang et al., 2005; Jamil et al.,
2016; Liebetanz et al., 2003). Primary sources of evidence in tACS
studies suggest that stimulation applied at an endogenous oscillatory
frequency for several minutes induces sustained after-effects (Ahn et al.,
2019b; Heise et al., 2016; Kasten et al., 2016; Wischnewski et al., 2018;
Zaehle et al., 2010), which are associated with NMDA receptor-medi-
ated plasticity (Wischnewski et al., 2018). This after-effect could even
be long lasting in the time scale of days to weeks after multiple sessions
of tACS (Ahn et al., 2019a). A recent longitudinal study investigated
alcohol intake and dopamine transporter (DAT) availability in the
striatum of people with alcohol use disorder (AUD) before and after
deep rTMS. With respect to sham stimulation, real stimulation sig-
nificantly reduced both alcohol craving and intake and DAT avail-
ability. This study suggested a potential clinical efficacy of rTMS in
throughout its modulatory effect on dopaminergic terminals
(Addolorato et al., 2017).
In some cases, longer and higher-amplitude stimulation induces
stronger and longer effects. For instance, enhanced clinical effects in
depressed patients are noted after doubling the number of rTMS pulses
(Hadley et al., 2011; Kaster et al., 2018); enhanced after-effects of tDCS
on cortical excitability can be induced by increasing the duration of
stimulation from a few seconds to several minutes (Nitsche et al.,
2003b; Nitsche and Paulus, 2000; Nitsche and Paulus, 2001). However,
further extension of stimulation duration and/or intensity does not
necessarily increase its efficacy (Esmaeilpour et al., 2018). Extending
the duration of anodal tDCS can convert after-effects from excitability
enhancement to diminution in some cases (Monte-Silva et al., 2013).
Increasing the current intensity of cathodal tDCS from 1 to 2mA re-
verses the effects from excitability diminution to enhancement
(Batsikadze et al., 2013). Similarly, doubling the duration of iTBS
converted its faciliatory after-effects into inhibitory while inhibitory
cTBS became faciliatory by doubling stimulation duration (Gamboa
et al., 2010). Likewise, increasing the TBS intensity converted its in-
hibitory effects to faciliatory (Doeltgen and Ridding, 2011). Decreasing
the intensity of 140 Hz tACS from 1mA in 0.2mA steps, generated
excitation at 1mA, no effect at 0.6 and 0.8mA, and inhibition at 0.4 mA
(Moliadze et al., 2012). Moreover, an increasing number of studies have
shown the relevance of a state-dependency of stimulation after-effects.
Thus, details of NIBS effects are dependent on a variety of factors and
may vary across brain regions in ways yet to be explored.
Based on the principle of homeostatic plasticity, stimulation that is
given simultaneously versus preceding or followed by another inter-
vention can change the effect of the primary stimulus. The direction of
synaptic plasticity may be due to regulatory mechanisms that aim to
prevent a ‘runaway’ effect of synaptic plasticity (Karabanov et al.,
2015). Moreover, effects of tES/TMS can also be affected by the
‘baseline’ brain state, in which the excitability profile of the brain area
might disrupt the expected mechanism of stimulation. These differ-
ential effects were for example observed when opposing effects of rTMS
were found in epileptic patients under excitability-inhibiting medica-
tion (Fregni et al., 2006). Cue exposure in PTSD patients differentiated
response to deep TMS (Isserles et al., 2013) and anodal tDCS resulted in
excitability diminution when it was applied to the motor cortex while
subjects performed voluntary muscle contraction
(Thirugnanasambandam et al., 2011). The above studies should be in-
terpreted with the caveat that “excitability” typically indicates re-
sponsiveness to one form of TMS and applied to the motor cortex.
Taken together, it should be kept in mind that neuroplastic after-effects
of tES/TMS are sensitive to stimulation parameters, but may also vary
across regions and brain state.
2.4. Timing: single vs. multiple sessions
In order to establish protocols for clinically relevant long-lasting
effects, an ongoing effort of research has been dedicated to exploring
the effects of repeating stimulation, either by applying stimulation daily
over several days or weeks, or repeating stimulation within a single
daily session, separated by a critical time window. In general, repeating
stimulation over multiple days has demonstrated efficacy in various
clinical applications, such as treatment of bipolar disorder, pain and
depression for tDCS (Sampaio-Junior et al., 2018; Kuo et al., 2014;
Sampaio-Junior et al., 2018), as well as treatment of depression using
rTMS (Rapinesi et al., 2015a; Senova et al., 2019). In fact, the number
of repetitions may even play a decisive role, as in one study, it was
found that at least 4–6 weeks of daily rTMS over left DLPFC was re-
quired to induce significant clinical improvement by active compared
with sham TMS (O’Reardon et al., 2007), whereas a parallel study
which performed rTMS for 3 weeks found no difference in response
between active and sham rTMS (Herwig et al., 2007).
With regard to addiction studies, positive evidence also exists for
lasting effects of repeated stimulation, such as reduced craving fol-
lowing a weekly application of tDCS over five weeks for alcohol ad-
diction (da Silva et al., 2013), enhanced abstinence rates for up to three
months following four sessions of iTBS for smokers (Dieler et al., 2014)
and reduced cigarette consumption and nicotine dependence for up to
six months following 13 sessions of rTMS (Dinur-Klein et al., 2014a).
However, even with these promising results, systematic or face-to-face
studies comparing different repetition intervals are missing, and are
crucially needed in order to determine effective repetition rates and
durations. The importance of this issue also underlies the need for de-
termining the optimal repetition intervals between sessions. In studies
using both tDCS and TMS, the duration of the repetition interval has
been found to be critical in modulating plasticity, while also avoiding
homeostatic mechanisms that may limit or counter-act plasticity
(Goldsworthy et al., 2013; Monte-Silva et al., 2013; Thickbroom, 2007;
Tse et al., 2018). For example, in a study on depression, repeating rTMS
twice daily with a 15-min interval between stimulation blocks resulted
in superior effects compared to a once daily application with the same
number of pulses (Modirrousta et al., 2018). For addiction, the number
of studies investigating the effect of interval timings remains scarce. In
a population of patients with alcohol dependency, five sessions of bi-
lateral tDCS over the DLPFC and administered twice daily for 13min
with a 20-min interval led to positive effects on relapse reduction and
improved the quality of life, which lasted for up to six months (Klauss
et al., 2014). In summary, although there is promising evidence for
persisting and long-lasting effects with repeated stimulation sessions,
the relatively large heterogeneity of these studies with regard to sti-
mulation technique, timing, repetition, and montage precludes a clear
understanding of how repetition may affect therapeutic outcomes in
SUD, warranting a need for systematic research designs (Trojak et al.,
2017).
2.5. Sham intervention
Adequate sham stimulation protocols are a critical factor in clinical
trials to ensure that effects can be ascribed specifically to tES/TMS. For
tES, blinding can be achieved by applying stimulation for a short
duration (10–30 s in different studies) with a fade in/out of the current
to induce a cutaneous sensation similar to that of the respective effec-
tive stimulation protocol. This method does not induce aftereffects, has
been shown to produce reliable blinding and is suitable for double-blind
experiments (Ambrus et al., 2012). Efforts to enhance sham reliability
are ongoing (Fonteneau et al., 2019; Garnett and den Ouden, 2015;
Kessler et al., 2012).
Since TMS generates sensory perceptions, such as clicking sounds,
and muscle contractions (Conde et al., 2019), sham strategies aim to
mimic the sight, sound, and feel of real stimulation, while attempting to
avoid any direct neuronal effects on the central nervous system. In
order to serve as a reliable control, for both, placebo and sensory effects
of TMS, sham TMS is either performed by tilting the coil away from the
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scalp (Sandrini et al., 2011), using sham-coils that include tangential
elements to the scalp surface similar to active coils without electro-
magnetic discharges (e.g. Levkovitz et al., 2015), and using electrical
stimulation under the coil to mimic muscle contractions. Specifically,
some sham coils use an electrical stimulator to apply a weak electrical
pulse time-locked to a TMS pulse to simulate the cutaneous sensation
associated with activating scalp muscles. These techniques have shown
the best similarity regarding the look, sound, and feeling of active sti-
mulation (Duecker and Sack, 2015; Mennemeier et al., 2009). Never-
theless, experienced participants may be able to discriminate between
active and sham TMS (Duecker and Sack, 2015; Rossi et al., 2007).
Sham TMS approaches require further development but may be suffi-
cient in clinical settings in which patients are generally naïve to TMS
(Duecker and Sack, 2015; Levkovitz et al., 2015; Sheffer et al., 2013a;
2013b).
Ultimately, the appropriateness of a specific sham protocol depends
also on the respective experimental design (e.g. it might be easier for
participants to discern between real and sham stimulation in crossover,
as compared to parallel group trials). There are ongoing efforts by the
TMS community to evaluate and revise sham protocols in order to in-
crease rigor across the field (Bikson et al., 2018a; Opitz et al., 2014).
2.6. Study Design: crossover vs. parallel vs. open label
When designing a brain stimulation study, several factors should be
considered in order to achieve reliable findings. These factors include
the choice of study population, the possibility of carry-over effects,
costs, subject compliance, and statistical power. Generally, studies that
do not expect to find high levels of inter-individual variability may opt
for parallel group designs. In these studies, two independent groups of
subjects receive either active or sham stimulation and are directly
compared. Consequently, one may need to recruit a relatively large
number of participants in order to find meaningful statistical effects.
When inter-individual variability is high, a crossover design may be
more beneficial. However, care must be taken to avoid carry-over ef-
fects, and unblinding may occur in patients that experience both active
and sham stimulation. Investigators may also consider parsimoniously
factorial designs where two features of a tES/rTMS intervention are
varied (e.g., intensity and duration) including a sham.
In open-label studies, both the researcher and the participant know
what type of stimulation/intervention the participant is receiving.
Though this may introduce bias in the experimental findings, an open-
label design might be used in spite of these weaknesses for pilot studies,
when the main question asked is if it is promising to conduct larger, but
more demanding sham-controlled trials. It should, however be kept in
mind that the interpretability of the results of those studies is seriously
limited. To explore the parameter space of stimulation to find the most
efficient parameter set, blinded pilot studies with sham arms are
mandatory.
3. Current status of evidence
A comprehensive literature search was conducted on PubMed with
articles from January 1, 2000 to July 1, 2018. Search terms are shown
in Supplementary Fig. 1 and included both TMS and tDCS studies in
SUD. For other tES modalities such as tACS/tPCS/tRNS (transcranial
alternating current stimulation, transcranial pulsed current stimulation,
or transcranial random noise stimulation), we ran a separate search
process, which did not return any articles with our inclusion/exclusion
criteria in that time frame. A combination of several key terms was used
to explore relevant TMS and tDCS articles. The exact combination used
is shown in Supplementary Fig. 1.
This search resulted in 218 articles for TMS and 632 articles for
tDCS. During the early stage of screening, two independent reviewers
(HT and NM) excluded 77 TMS and 558 tDCS records based on their
titles and abstracts. Exclusion criteria included: (1) non-peer reviewed
book chapters, (2) commentaries, (3) author corrections, and (4) dis-
orders other than substance use disorders (SUDs).
The yield, which included 141 articles for TMS and SUDs and 74 for
tDCS and SUDs, were evaluated to identify eligible articles. After an in-
depth full-text review, 50 TMS articles and 34 tDCS articles were included
in the final evaluation. The exclusion criteria at this stage included: (1)
review articles, (2) studies with healthy subjects only, (3) case reports, (4)
studies with subjects other than humans, (5) basic physiology studies, (6)
study protocols, or (7) letter to the editors. One TMS study was duplicated
with another title. In addition, single or paired-pulse TMS studies were re-
moved; only repetitive TMS (rTMS) studies were included as we were in-
terested in studies with therapeutic goals, not basic neurophysiology. The
PRISMA charts for the inclusion/exclusion procedures for rTMS and tDCS
studies are shown in Fig. 2 panel A and B, respectively.
Fig. 2. PRISMA flow diagrams for published rTMS (panel A) and tDCS (panel B) trials in drug addiction.
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3.1. Contribution of countries and drug classes
Among the yield of 84 total articles, 19 articles had corresponding
authors from the United States of America (USA), followed by Brazil
(n= 13), Italy (n=11), China (n= 10) and Germany (n=8).
Fourteen countries were represented in the extant published literature.
Countries reported different proportions of rTMS vs. tDCS studies
(Fig. 3).
Countries targeted different substances: cocaine studies were re-
ported from the USA, Italy, and Brazil; methamphetamine studies from
China, Iran, and USA; and heroin/opioid studies only from China
(Fig. 4). It is notable that there were 3 articles with 2 drugs as targets.
Two out of these 3 articles reported a single trial including patients with
two drug use disorders (cocaine or alcohol) (Hanlon et al., 2017;
Nakamura-Palacios et al., 2016) and one article including 2 in-
dependent trials for cocaine and alcohol (Kearney-Ramos et al., 2018).
As these two trials were identical in their design, they were counted as a
single study. As a result, the number of articles and studies (trials) in
this manuscript are the same (n=84).
3.2. Number of subjects and sex proportion
Forty-seven studies were reported as parallel design, 33 crossover,
and 4 single arm trials. Seventy-five (87%) studies had 30 or fewer
subjects in each arm; 10 studies had 30 or more subjects in each arm.
From all 84 studies, 11 studies did not report the number of female vs.
male participants; 26 studies included only males. In 21 studies the
percentage of female participants was 40% or less. Twenty studies had
40–70% female participants; in 6 studies the proportion was greater
than 70%. In one study, all participants were female (Hoppner et al.,
2011).
3.3. Targeted brain areas
The left DLPFC was the most frequent anatomical target followed by
the right DLPFC. In addition, there were seven other brain areas tar-
geted: frontal pole (FP), temporoparietal (TP), inferior frontal gyrus
(IFG), superior frontal gyrus (SFG), and motor cortex. There were seven
studies that used TMS intended to target deeper and wider regions in-
cluding anterior cingulate cortex (ACC) and insula (Table 1, Fig. 5). For
TMS it is relativity well established that the primary outcome is the
activation of the cortex under the TMS coil (Opitz et al., 2011), with
secondary activation of networks through synaptic connectivity (Opitz
et al., 2016).
For conventional tES (tDCS/tACS), using large electrodes, compu-
tational models (DaSilva et al., 2015; Datta et al., 2009; Santos et al.,
2016) supported by intra-cranial recordings (Huang et al., 2017; Opitz
et al., 2013) and imaging studies (Krishnamurthy et al., 2015; Lang
et al., 2005) indicate diffuse current flow under and between electrodes
representing a large area of potentially stimulated cortex.
3.4. Dosage, number of sessions and follow up
Among 50 TMS studies, nearly half of them (49%) applied 10 Hz
pulses to the subjects, 24% used 20 Hz, and 12% performed 1 Hz sti-
mulation. The remained applied 5 and 15 Hz, and in 1 study subjects
received 50 Hz pulses in the form of iTBS. The numbers of pulses in a
session of TMS are 2000 or less for 82% of TMS studies. In 34 tES trials,
2 mA is the most frequent intensity (21 trials), and second place goes to
1mA with 10 trials. 0.45mA and 1.5 mA each have 2 trials. In term of
duration, 88% of tES trials have 20min stimulation or less.
Thirty-seven (44%) tES/TMS trials included only one session of
stimulation. Eighteen (21%) had 2–7 sessions of the intervention and 20
(24%) had 8–14 sessions. Nine studies delivered more than 14 sessions
(11%) all using TMS; three administered 15 sessions and six adminis-
tered 20 sessions. Sixty (71%) studies did not include any follow up
beyond the day of the intervention. There were only two studies with
one-year follow-up, six studies with six months follow-up, and four
studies with three months follow-up. Twelve studies had fewer than
three months follow-up.
3.5. When to stimulate
There were four distinct time intervals at which rTMS/tDCS inter-
ventions were administered: (1) before the participant sought standard
treatment (2) while the subject was treatment seeking but before un-
dergoing standard treatment, (3) within the first month of standard
treatment (mainly detoxification and stabilization) and (4) after the
initial recovery period (more than one month).
All studies in tobacco dependent participants were conducted before
starting standard treatment, but strategies addressing other drugs of use
were varied (Fig. 6). Seven studies explicitly added rTMS/tDCS to a
pharmacotherapy program that included the following: diazepam
(n= 3), trazodone (n= 1), nicotine (n= 2), and zolpidem (n=1). Six
Fig. 3. Contribution by country of tDCS/rTMS studies (n=84) for addiction medicine, color coded for type of stimulation (Y axis represents number of studies).
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studies were combined with psychological interventions. Thirty-four
(40%) studies used cue exposure before or during stimulation with the
goal of increasing efficacy. There is a growing body of evidence on
using tES/TMS to reduce opioid use in healthy people for pain man-
agement (e.g., post-surgery) before dependence can start (Borckardt
et al., 2017, 2013). This is an interesting field but it is beyond the scope
of this review.
3.6. Outcome measures
Sixty-four (76%) studies used craving as their primary outcome
measure. Self-report on a visual analogue scale (VAS) was the most
frequently used craving measure (30 studies). Eighteen different ques-
tionnaires were used to measure drug craving for different drugs with
variations in items and structure. Forty-four (52%) articles used change
in drug use frequency/amount as an outcome measure. However, only
14 used objective measures such as urine drug tests or breath analyzers.
Thirty-six studies (81%) used self-report measures for drug use or ad-
diction severity. Other outcomes such as positive valence (e.g., moti-
vation, willingness, and hedonic tone) (n=6), negative valence (e.g.,
depression, anxiety, and withdrawal) (n= 22), cognition (e.g.,
memory, attention, and inhibition) (n= 20), general mental or physical
health (e. g., daily functioning, quality of life and sleep) (n=10),
neurophysiologic measures (e.g., ERP, fMRI, and fNIRS) (n=27) were
also included in the reviewed studies (Fig. 7 and Table 2).
4. Clinical targets and outcomes in tES/TMS trials for addiction
medicine
Selecting suitable outcome measures for tES/TMS trials in SUDs is
always a challenging process. Like any other field, outcome measures
need to have high validity (face validity, content validity, and construct
validity), reliability (test-retest and inter-rater), variability (broad dis-
tribution and range of values), responsiveness (ability to detect change
in an individual over time) and feasibility in the clinical context of the
trial. As previous sections have mentioned, there is significant varia-
bility in the experimental designs employed and the patient populations
investigated to date. This variability also extends to the outcome
measures that have been evaluated in these trials. In this section, we
will introduce standard behavioral and biologic measurement assays
that are recommended as robust endpoints for clinical trials in
addiction medicine. Some questions include: “What outcome measures
should be used in tES/TMS clinical trials of participants with SUDs?”,
“What are governmental standards (e.g. FDA) on outcome measures?”,
“Are there ‘gold standard’ assessment tools and biomarkers that should
be used for evaluating NIBS efficacy in various domains of SUD?” In this
section, we provide the reader with some tangible suggestions for de-
pendent measures to consider in neuromodulation studies of SUD.
4.1. Primary endpoint: consumption
To date, the majority of therapeutic agents being used to treat SUDs
have received FDA-approval based on their ability to decrease con-
sumption. The gold standard for evaluating efficacy of a therapeutic
agent for SUDs is its ability to stop consumption of the substance being
used or to reduce consumption to less harmful levels (harm reduction).
For example, there are currently four FDA-approved pharmacotherapies
for alcohol use disorder – disulfiram, oral naltrexone, extended release
injectable naltrexone, and acamprosate. Disulfiram, acamprosate, and
oral naltrexone were approved for increasing abstinence more than
placebo, whereas extended release injectable naltrexone was approved
for increasing the proportion of subjects with no heavy drinking days.
Within alcohol treatment research alcohol consumption is frequently
measured by patient’s self-report (e.g. the time line follow back method
(Sobell et al., 1996)) but can also include biological measures, such as
urine ethyl glucuronide (ETG; a measure of recent drinking) and per-
cent carbohydrate deficient transferrin (%CDT; a measure of drinking
over several days). Unfortunately, available biomarkers for alcohol use
tend to have poor sensitivity and specificity (Tavakoli et al., 2011).
There are also three FDA approved medications for smoking cessa-
tion: nicotine replacement therapies (NRTs), bupropion, and vareni-
cline –all of which promote abstinence. As with the alcohol use litera-
ture, consumption is frequently measured by self-report, but can also
include biological verification such as exhaled carbon monoxide (a
measurement of recent use of a combustible agent), or urine cotinine (a
metabolite of nicotine). As the methods of delivery for nicotine are
evolving and there is a rise of smoking non-tobacco products (e.g.
marijuana), a positive carbon monoxide (CO) level may not be suffi-
cient to conclude that someone is smoking tobacco. Combining CO with
a urine drug screen and/or urine cotinine may provide a more robust
assessment.
Treatment for opioid use disorder typically requires acute
Fig. 4. The number of tDCS/rTMS studies from each country color coded according to substance type (n= 84 but 3 studies included 2 drugs).
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detoxification and/or opioid maintenance treatment (i.e., medication
assisted treatment). The two primary treatments for opioid use disorder
(methadone, buprenorphine) are designed for long term opioid main-
tenance therapy. Methadone is a mu-opioid receptor agonist whereas
buprenorphine is a partial mu-opioid receptor agonist (mu agonist-K
antagonist). As with the other classes of substances both self-report and
urine drug screens are used for biological verification of consumption.
The challenge with opioids is that a general opioid screen will detect
morphine and many of its metabolites (e.g. Demerol) but not oxyco-
done. Oxycodone and buprenorphine often have to be assessed with a
specific assay. Additionally, as worldwide production and export of
synthetic compounds is evolving, many of these newer compounds are
not detected by typical hospital screening tools.
Although there are currently no FDA-approved pharmacotherapies
for cocaine use disorder or methamphetamine use disorder, consump-
tion of these drugs can (and should) also be assessed with biological
metrics as well as self-report whenever possible.
*Suggestions for measuring consumption: Whenever possible bio-
markers (e.g. ETG, CDT, CO, cotinine, opioid metabolites, and cocaine
metabolites) of drug consumption should be assessed repeatedly ac-
cording to the dissipation rate of the biomarker (for example, CO
vanishes within hours while cotinine can be detected over a week after
smoking). Additionally, the timeline follow back (TLFB) interview is the
gold standard method for assessing days of use (e.g., 30 days) with the
caveat that it relies completely on self-report. For longitudinal studies
at least a 3 months follow-up period is recommended. The TLFB can be
used to create summary measures, including the percentage of days
abstinent from substances, number of days used in last month, and
number of days used at a high level in last month (i.e. heavy drinking
days). See (Donovan et al., 2012) for a thorough review of primary
outcome measures in SUD treatment research.
4.2. Surrogate endpoints
Although a reduction or elimination of the consumption of the drug
is the ultimate endpoint for clinical trials research, there are also many
other behavioral and biologic variables that have been studied ex-
tensively and are considered meaningful surrogate endpoints for pa-
tients seeking treatment for SUDs. Many of these behavioral domains
are described below, appear to be present across multiple types of drug
using populations, and have also been observed in preclinical models of
drug use (e.g. heightened reactivity to predictive drug cues,
Table 1
Protocols used to stimulate specific areas with tDCS/rTMS (n (number of studies)= 84).
Target Type (n) Protocol Outline (n)
Right DLPFC TMS (n= 15) rTMS 10 Hz (n= 6) [1], [2], [3], [4], [5], [6]
20 Hz (n= 6) [7], [8], [9], [10], [11], [12]
iTBS 50 Hz bursts in 5 Hz (n= 1) [13]
rTMS 1 Hz (n= 1) [14]
rTMS 10 Hz and 1 Hz (n= 1) [15]
tDCS (n= 17) Anodal tDCS Cathode on left DLPFC (n= 15) [16], [17], [18], [19], [20], [21], [22], [23], [24], [25], [26], [27], [28], [29],
[30]
Cathode on supraorbital (n= 1) [31]
Cathode on occipital region (n=1) [32]
Left DLPFC TMS (n= 29) rTMS 10 Hz (n= 16) [4], [6], [33], [34], [35], [36], [37], [38], [39], [40], [41], [42], [43], [44], [45], [46]
15 Hz (n= 3) [47], [48], [49]
20 Hz (n= 5) [12], [50], [51], [52]
10 Hz and 20 Hz (n= 1) [53]
Deep TMS 15 Hz (n= 1) [54]
rTMS 1 HZ (n= 1) [55]
rTMS 10 Hz and 1 Hz (n= 2) [15], [56]
tDCS (n= 19) Anodal tDCS Cathode on right DLPFC (n= 10) [21], [25], [27], [28], [29], [30], [57], [58], [59], [60]
Cathode on supraorbital (n= 9) [61], [62], [63], [64], [65], [66], [67], [68], [69]
Bilateral DLPFC TMS (n= 5) Deep TMS 10 Hz (n= 2) [70], [71]
20 Hz (n= 3) [72], [73], [74]
Left FP TMS (n= 3) cTBS 50 Hz bursts in 5 Hz (n= 2) [75], [76]
rTMS 5 Hz (n= 1) [77]
SFG (FpZ) TMS (n= 1) rTMS 10 Hz and 1 Hz (n= 1) [78]
Bilateral DLPFC and ACC TMS (n= 1) Deep TMS 10 Hz and 1 Hz (n= 1) [79]
Bilateral DLPFC and Insula TMS (n= 1) Deep TMS 10 Hz and 1 Hz (n= 1) [80]
Bilateral TP tDCS (n= 2) Cathodal tDCS Anode on occipital region (n=2) [81], [82]
Right IFG tDCS (n= 1) Anodal tDCS Cathode on supraorbital (n= 1) [65]
Left TP tDCS (n= 1) Cathodal tDCS Anode on right TP (n= 1) [81]
Motor cortex tDCS (n= 2) Anodal tDCS Cathode on supraorbital (n= 2) [83], [84]
DLPFC, dorsolateral prefrontal cortex: IFG, inferior frontal gyrus; FP, frontal pole; TP, temporoparietal; SFG, superior frontal gyrus; ACC, anterior cingulate cortex.
[1], (Mishra et al., 2016); [2], (Qiao et al., 2016); [3], (Jansen et al., 2015); [4], (Mishra et al., 2015); [5], (Mishra et al., 2010); [6], (Camprodon et al., 2007); [7],
(Kozak et al., 2018); [8], (Herremans et al., 2016); [9], (Herremans et al., 2015); [10], (Herremans et al., 2013); [11], (Herremans et al., 2012); [12], (Wing et al.,
2012); [13], (Dieler et al., 2014); [14], (Trojak et al., 2015); [15], (Liu et al., 2017); [16], (Klauss et al., 2018a); [17], (Shahbabaie et al., 2018a); [18], (Nakamura-
Palacios et al., 2016); [19], (Wietschorke et al., 2016); [20],(Batista et al., 2015); [21], (Pripfl and Lamm, 2015); [22], (Conti et al., 2014); [23], (Conti and
Nakamura-Palacios, 2014); [24], (Klauss et al., 2014); [25], (Gorini et al., 2014); [26], (Fecteau et al., 2014); [27], (Pripfl et al., 2013); [28], (Boggio et al., 2010);
[29], (Boggio et al., 2008); [30], (Fregni et al., 2008); [31], (Shahbabaie et al., 2014); [32], (Mondino et al., 2018); [33], (Kamp et al., 2018); [34], (Liang et al.,
2018a); [35], (Zhang et al., 2018); [36], (Li et al., 2017a); [37], (Li et al., 2017b); [38], (Sahlem et al., 2017); [39], (Su et al., 2017); [40], (Del Felice et al., 2016);
[41], (Huang et al., 2016); [42], (Shen et al., 2016); [43], (Prikryl et al., 2014); [44], (Pripfl et al., 2014); [45], (Li et al., 2013a); [46], (Amiaz et al., 2009); [47],
(Pettorruso et al., 2018); [48], (Terraneo et al., 2016); [49], (Politi et al., 2008); [50], (Sheffer et al., 2018); [51], (Hoppner et al., 2011); [52], (Eichhammer et al.,
2003); [53], (Sheffer et al., 2013a; 2013b); [54], (Rapinesi et al., 2016); [55], (Li et al., 2013b); [56], (Baker et al., 2017); [57], (Yang et al., 2017); [58], (den Uyl
et al., 2017); [59], (de Almeida Ramos et al., 2016); [60], (Boggio et al., 2009); [61], (Vitor de Souza Brangioni et al., 2018); [62], (den Uyl et al., 2016); [63],
(Falcone et al., 2016); [64], (Kroczek et al., 2016); [65], (den Uyl et al., 2015); [66], (Smith et al., 2015); [67], (da Silva et al., 2013); [68], (Xu et al., 2013); [69],
(Nakamura-Palacios et al., 2012); [70],(Iran Supreme Leader, 2006); [71], (Bolloni et al., 2016); [72], (Girardi et al., 2014); [73], (Rapinesi et al., 2015b); [74],
(Ceccanti et al., 2015); [75], (Hanlon et al., 2017); [76], (Kearney-Ramos et al., 2018); [77], (Hanlon et al., 2016a; 2016b);[78], (Rose et al., 2011); [79], (Martinez
et al., 2018); [80], (Dinur-Klein et al., 2014b); [81], (Meng et al., 2014); [82], (Wang et al., 2016); [83] (Batsikadze et al., 2017); [84], (Grundey et al., 2012).
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perseverative responding, delayed discounting for the drug, response to
stress, narrowing of the behavioral repertoire) (Beveridge et al., 2008;
Garavan and Hester, 2007; Stalnaker et al., 2009).
4.2.1. Cue-reactivity and self-reported craving
One domain that pharmacotherapy, behavioral treatment, and brain
stimulation intervention researchers have embraced is “craving” and its
closely related construct “cue-reactivity.” Of the published studies using
brain stimulation as a treatment for SUDs thus far, the most common
dependent measure has been self-reported craving. While craving is
now included in the DSM-5 as a core symptom of SUD, its inclusion has
been controversial, due in part to challenges in defining ‘craving’
(Sayette et al., 2000). Support for craving as a key treatment target for
SUD comes from multiple behavioral, imaging, pharmacology, and
genetics studies (Ekhtiari et al., 2016; Garrison and Potenza, 2014;
Haass-Koffler et al., 2014; Sinha, 2009; Tiffany and Wray, 2012). Self-
reported craving, however, is often very subjective and is not as closely
related to relapse as biological markers of cue-sensitivity (for review
see: Hanlon et al., 2016a; 2016b)). This may be because craving as a
construct requires that participants have insight into something that is a
fairly complex psychological phenomenon. It may also be related to the
relatively imprecise ways in which it is sometimes measured (e.g. often
on a 1–5 numerical rating scale; (Kavanagh et al., 2013)).
Cue-reactivity is another common dependent measure and can be
measured in a more objective manner using behavioral paradigms (e.g.
attentional bias) or biological metrics (e.g. EEG, fMRI, pupil dilation,
heart rate). Elevated drug-cue elicited brain activity is one of the most
widely cited, transdiagnostically relevant traits of current SUD popu-
lations. Several retrospective meta-analyses have described that the
medial prefrontal cortex and cingulate cortex are reliably activated to
drug cues (Schacht et al., 2013). Other meta-analyses have shown that
activity in these brain regions may predict relapse across multiple
substances (Courtney et al., 2016; Killen and Fortmann, 1997).
As with the suggestion that any clinical research study measuring
consumption include a biologic metric (as well as self-report), we
highly recommend that studies measuring craving/cue reactivity in-
clude a biologic metric, as well as self-report.
*Suggestions for measuring craving/cue-reactivity: Biologic ver-
ification of cue-reactivity (functional MRI, DA and Glutamate PET, eye-
tracking/pupilometry, startle response, EEG, physiologic measurements
of heart rate, and blood pressure) and self-report measures such as
Tiffany Cocaine Craving Inventory (Tiffany et al., 1993), Brief Ques-
tionnaire of Smoking Urges (QSU) (Cox et al., 2001), Obsessive Com-
pulsive Drinking Scale (OCDS) (Anton et al., 1995), Alcohol Urge
Fig. 5. Brain targets for TMS/tDCS trials in addiction medicine. Right panel: Seventy seven out of 84 published TMS/tDCS studies (till June 1, 2018) selected DLPFC
as the target of stimulation including right, left, or bilateral DLPFC. Each trial with bilateral stimulation counted in both right and left categories. In 13 tDCS studies,
one of the electrodes was placed on right supraorbital area (counted as frontal pole). All deep TMS (dTMS) studies are bilateral with both high and low frequency (HF
and LF) TMS. Left panel: The number of TMS and tDCS studies in each target. DLPFC, dorsolateral prefrontal cortex; ACC, anterior cingulate cortex; FP, frontal pole;
SFG, superior frontal gyrus; IFG, inferior frontal gyrus; TP, temporoparietal and M1, motor cortex.
Fig. 6. Phases of recovery during which tDCS/rTMS was administered, divided amongst SUD groups.
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Questionnaire (AUQ) (Bohn et al., 1995), Alcohol Craving Ques-
tionnaire (ACU) (Raabe et al., 2005), Penn Alcohol Craving Scale
(PACS) (Flannery et al., 1999) and Desire for Drug Questionnaire
(DDQ) (Franken et al., 2002). Since craving is a potentially transdiag-
nostic outcome across different SUDs, there are attempts in developing
standardized versions of the above measures/questionnaires that can be
used across substances (Franken et al., 2002). There is an ongoing de-
bate that simple scales like single item visual analogue scales (VAS)
have face validity but lack content or predictive validity (limited to
measure complex multifaceted aspects of craving). Meanwhile, there
are hopes for simple craving or drug use self-reports using ecological
momentary assessment (EMA) (Jones et al., 2019).
4.2.2. Cognitive and behavioral markers of SUD
While consumption (e.g. smoking cessation, reductions in alcohol
use) is the dependent measure currently deemed most important for
FDA approval, there are a number of phenotypes that are associated
with SUDs and vulnerability to relapse. These include indices of ex-
ecutive control (i.e., inhibitory control, working memory), stress re-
activity/distress tolerance (Kwako and Koob, 2017), reward processing
(Volkow and Morales, 2015), and assigning value to future rewards
(e.g. delayed discounting). tES/TMS may be able to modulate neural
systems that orchestrate these cognitive processes and improve per-
formance in executive function and decision-making measures. Some of
these measures (i.e. risk-taking and uncertainty-based decision-making)
are also meaningfully related to clinical outcomes in addiction medi-
cine (e.g. treatment retention, drug relapse) (Dominguez-Salas et al.,
2016). tES/TMS trials in addiction medicine can benefit from adopting
a “gradients of transference” approach by testing the link between sti-
mulation/inhibition and (1) related cognitive performance, (2) cogni-
tion-related clinical outcomes. However, there are serious concerns
regarding the validity and reliability of currently available behavioral
tasks in decision making and self-control (Enkavi et al., 2019).
*Suggestions for measuring cognitive and behavioral markers of
SUD before and after NIBS treatment:
Inhibitory control (Go/No Go; Kaufman et al., 2003), working
memory (N-Back; Watter et al., 2001), temporal processing (Delay
Discounting Bickel, 2015), stress reactivity/distress tolerance (TSST;
Kirschbaum et al., 1993); personalized guided imagery (Sinha, 2013);
risky decision making (Iowa Gambling Task (Bechara et al., 1997) and
reward processing (MID; Knutson et al., 2001) could be some of the
domains and measures.
4.2.3. Comorbidity and psychosocial correlates of substance use
SUDs are often associated with psychiatric comorbidities (e.g. de-
pression, anxiety), social and environmental deficits (e.g. negative
consequences, environmental reward, drug free social network), and
poor quality of life with each contributing to a lower likelihood of
sustained recovery (Kiluk et al., 2019; Tiffany et al., 2012; Witkiewitz
et al., 2019). While an improvement in any of these factors has not yet
Fig. 7. Major groups of outcome measures in 84 tDCS/rTMS studies.
Table 2
Outcome measures in tDCS/rTMS studies.
Outcome (rTMS/tDCS) Types of Outcome (rTMS/tDCS)
Craving (38/26) General craving (28/17)
Cue-induced craving (11/10)
Implicit craving (0/5)
Positive Valence (5/1) Hedonic tone (1/0)
Willingness (1/0)
Motivation (2/1)
Intensity of enjoyment in chest sensations (1/
0)












Cognitive Functions (11/9) General cognitive performance (2/4)
Attention/Working memory (5/2)
Memory and learning (2/0)
Executive function/Inhibition (2/0)
Decision making (1/3)
Neurophysiology (14/13) Brain activity (fMRI, ERP, fNIRS) (7/9)
Brain connectivity (fMRI, DTI) (7/3)
Neurophysiological effects (EEG, Heart rate)
(2/2)
Dopamine transporter (PET) (1/0)
Cerebral hemodynamic indices (Transcranial
Doppler sonography) (1/0)
Metabolites (MRS) (2/0)
Motor cortex excitability (0/2)
Others (2/0) Adherence (1/0)
Tolerability (1/0)
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been the focus of FDA approval, from a clinical perspective it is clear
that if a brain stimulation intervention could impact any of these as-
sociated factors, there would be a large reduction in social costs asso-
ciated with SUD.
*Suggestions for measuring functional and health correlates: Short
Inventory of Problems from Alcohol and Drug Use (SIP–AD) or broader
quality of life measures like WHOQOL-BREF (Skevington et al., 2004)
or 36-item short-form health survey (SF-36) (Ware and Sherbourne,
1992).
5. tES/TMS interactions with contextual treatments and
comorbidities
5.1. Contextual treatments (treatment as usual)
The literature to date has been mixed with respect to the efficacy of
tES/TMS on SUDs (Spagnolo and Goldman, 2017). Among the various
neuromodulation modalities used to treat SUDs, short-term treatment
with rTMS and tDCS have shown beneficial effects on both drug con-
sumption and craving (Coles et al., 2018). Nevertheless, optimal sti-
mulation parameters (i.e., duration, number of stimulation treatments,
stimulation frequency, intensity, brain region of target and proximity
between treatments) have yet to be established (Shahbabaie et al.,
2018b). Thus, parsing the different contextual parameters among these
trials might lead to more efficient outcomes for targeted treatment of
SUDs with or without comorbidities.
Time of Intervention may be a critical component to successful
treatment. Treatments for SUDs are typically administered within three
stages: 1) pretreatment (i.e., aiding individuals who are considering
entering treatment/changing their behavior), 2) detoxification (i.e.,
helping individuals reduce/eventually quit a substance), or 3) in a long-
term recovery phase (i.e., administered post-abstinence as a relapse
prevention strategy).
5.1.1. Pretreatment intervention
Individuals recruited for participation in a study with a neuromo-
dulation intervention before starting their SUD treatment (treatment
seeker or non-treatment seeker) should be assessed for motivation, in-
sight, and concurrent risky behavior (Bari et al., 2018). Frequently,
individuals with SUD are incentivized towards study participation for
financial reasons, or other social, economic, and psychological stressors
(Luigjes et al., 2015). These contextual factors should be considered
carefully as well.
5.1.2. Interventions during detoxification
Following multiple failed detoxification attempts individuals with
SUDs may resort to novel interventions such as neuromodulatory
techniques to aid in quitting (Bari et al., 2018). Given that the critical
period for relapse is within the first few days of abstinence, therapeutic
approaches that target both acute cravings and withdrawal symptoms
are warranted (Trojak et al., 2015). Several studies have shown pro-
mising anti-craving/withdrawal effects of TMS, including reducing
drug-seeking and risk-taking behaviors (Jansen et al., 2013; Liang et al.,
2018b).
5.1.3. Interventions during long-term recovery
Although the efficacy of neuromodulatory treatments has been
promising during detoxification, a major issue facing treatment provi-
ders is the high risk of relapse following successful treatment. Non-in-
vasive neuromodulation treatments notably produce temporary effects
(i.e., tDCS and TMS) compared to long-term benefits found with more
directly-targeted neuromodulatory therapies (i.e., DBS) (Bari et al.,
2018). Moreover, studies have shown that there are lower relapse rates
after treatment discontinuation when behavioral therapies are com-
bined with medications or neuromodulatory treatments (Jansen et al.,
2013). Although the research in this area is limited, there is currently a
large momentum to design clinical trials that combine a behavioral
prime or a behavioral intervention with the neuromodulation strategy
(Section 5.3). This may be particularly valuable in tES literature given
the portability of the technology and the ease with which it can be
combined with evidence-based behavioral interventions for SUD such
as cognitive behavioral therapy, exposure therapy, or contingency
management. Thus, given the multifaceted nature of addiction and its
treatment, including psychotherapeutic processes like motivational
enhancement and cognitive behavioral treatment may be useful as add-
on long-term therapies with tES/TMS (Bari et al., 2018).
5.2. Comorbidities with SUDs
Neuromodulatory treatments have also been used for comorbidities
with SUDs (Coles et al., 2018). One group studying smokers with
schizophrenia demonstrated that rTMS reduced cigarette cravings
compared to sham (Wing et al., 2012). In contrast, another study of
tDCS in comorbid individuals with schizophrenia and tobacco depen-
dence found no effect on craving or consumption (Smith et al., 2015).
Another group using rTMS for comorbid dysthymia and alcohol use
disorder, showed decreased alcohol consumption with rTMS (Ceccanti
et al., 2015). Finally, a case report of using DBS to treat a woman with
refractory OCD resulted in reduced craving and consumption of cigar-
ettes (Mantione et al., 2015). Perhaps a dual benefit of brain stimula-
tion treatments targeting underlying neurobiological factors in SUDs
may also extend to deficiencies found in other psychiatric disorders
(i.e., nicotinic acetylcholine receptor deficits found in schizophrenia
patients, associated with both higher smoking rates and cognitive
dysfunction) (Lucatch et al., 2018).
5.3. Combination interventions with tES/TMS
While neuromodulatory techniques are a promising interventional
approach in treatment of SUDs but most responses are partial, and even
well-documented anti-craving effects of rTMS, do not necessarily
translate into reduction in drug use or abstinence (Wing et al., 2013).
Combining neuromodulation with behavioral and pharmacotherapeutic
interventions may ultimately mitigate these shortcomings.
5.3.1. Cognitive and behavioral interventions (CBT, cognitive training/
retraining)
In the treatment of SUDs, behavioral interventions (i.e., motiva-
tional interviewing (MI); cognitive behavioral therapy (CBT); con-
tingency management (CM)) have all been used with varying effec-
tiveness to support abstinence and prevent relapse. Accordingly,
neuromodulation treatment, like pharmacotherapies, should be seen as
an adjunct to behavioral treatment of addiction to ensure prolonged
recovery (Spagnolo and Goldman, 2017). For instance, plateaued re-
sponse from DBS was further improved when structured CBT was added
(Widge et al., 2016). Another study delivered rTMS as an adjunctive
treatment to transdermal nicotine and group therapy, resulting in de-
creased craving. However, no differences in smoking were found be-
tween active and sham conditions (Wing et al., 2012). Given the level of
motivation needed to change a behavior, ensuring that a solid beha-
vioral modification framework of recovery is in place is critical for ef-
fective outcomes in neuromodulation trials. Cognitive deficits asso-
ciated with decreased prefrontal functioning have been related to SUDs
(Kozak et al., 2017) and increased risk of relapse (Dominguez-Salas
et al., 2016). Given that neuromodulation can improve cognitive con-
trol/functioning, it may (in part) diminish the risk for relapse by
strengthening cognitive control (Jansen et al., 2013; Schluter et al.,
2018).
5.3.2. Pharmacotherapies
Though limited, combining pharmacological treatments with brain
stimulation methods has an advantage of reversing plasticity induced
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by drugs of abuse by targeting the neurocircuits that maintains addic-
tive behaviors (Salling and Martinez, 2016). For instance, nearly 50% of
patients become abstinent from cigarettes after treatment with rTMS
concurrent with nicotine replacement therapy (Trojak et al., 2015). One
study found that adjunctive treatment of rTMS with pharmacotherapy
showed improvements in depressive symptoms and craving for alcohol
(Rapinesi et al., 2015a).
6. Perspectives on tES/TMS for non-substance-related addictive
behaviors
Non-substance-related addictive disorders are frequently comorbid
with and share some neurobiological substrates and behavioral mani-
festations of substance-related addictive disorders. This is particularly
true for gambling disorder. It is thus an important question of whether
neuromodulation could change these neurobiological vulnerabilities,
and thereby have clinical value for non-substance addictive behaviors
as well.
Gambling disorder was recognized as the first behavioral addiction,
and as such was reclassified within the category of “Substance-related
and Addictive Disorders”, in the Diagnostic and Statistical Manual of
psychiatric disorders (DSM-5) in 2013. In the ICD-11, gambling dis-
order was classified within the same super-category of disorders due to
substance use or addictive behaviors. In the DSM-5, gaming disorder
was placed in the Appendix as a condition requiring more research.
There is abundant evidence on similarities between gambling disorder
and SUDs regarding genetics, neurobiology, psychological processes,
and effectiveness of psychological treatment (Goudriaan et al., 2014).
In gambling disorder, a neurocognitive profile showing diminished
executive functioning compared to healthy controls (e.g. diminished
response inhibition, cognitive flexibility) was related to differential
functioning of the DLPFC and anterior cingulate cortex (ACC), both part
of the cognitive control circuitry (van Holst et al., 2010). Moreover,
increased neural cue reactivity and associated self-reported craving are
present in the striatum, orbitofrontal cortex and insular cortex in
gambling disorder compared to healthy controls. Abnormal reward and
loss processing is evidenced by differential orbitofrontal cortex (OFC)
functioning in gamblers and is thought to underlie processes like per-
sistence in gambling despite losses (Clark et al., 2018).
These abnormalities in cognitive-motivational behavioral and
frontostriatal functioning in gambling disorder warrant the question of
whether tES/TMS may be a promising add-on treatment for gambling
disorder and other non-substance-related addictive behaviors. tES/TMS
may normalize some of these endophenotypic markers, for instance by
enhancing cognitive control through DLPFC stimulation.
Neuromodulation like tDCS and rTMS have been shown to reduce
craving in substance related disorders (Jansen et al., 2013), and
changes in cognitive functioning, mostly indicating improvement of
cognitive functioning in addictive disorders following tES/TMS
(Schluter et al., 2018). Currently, a very limited number of tES/TMS
pilot studies in gambling disorder are present. For instance, in a single
session pilot study in nine problem gamblers, high frequency rTMS
reduced desire to gamble, whereas cTBS reduced blood pressure, but
had no effects on desire to play (Zack et al., 2016). In this same study no
effects on impulsive behavior (delay discounting) and Stroop inter-
ference were evident. In a sham-controlled cross-over high-frequency
rTMS study (left DLPFC), active rTMS diminished craving compared to
sham rTMS (Gay et al., 2017). Yet in another trial, low-frequency rTMS
over the right DLPFC had similar effects as sham stimulation on
craving, though with a large placebo effect (Sauvaget et al., 2018). In a
neuroimaging study, active tDCS changed GABA levels in the prefrontal
cortex in problem gamblers, but glutamate levels were unaffected, as
indicated by magnetic resonance spectroscopy (Dickler et al., 2018).
Thus, from these few studies it appears that tES/rTMS has the ability to
alter at least some of the working mechanisms that underlie patholo-
gical gambling.
As DLPFC targeted TMS has been shown to not only change DLPFC
functioning, but also to lead to changes in frontostriatal connectivity in
immediate single-session studies in addiction (Jansen et al., 2015), fu-
ture studies could target the DLPFC in gambling disorder to target the
relevant underlying neural circuitry. Rigorously conducted clinical
trials are needed to investigate whether tES/TMS and what type of
stimulation (e.g. DLPFC stimulation; insular stimulation; cTBS) has the
potential to improve cognitive functioning, diminish craving, and/or
reduce gambling behavior in disordered gambling.
7. Laterality of stimulation in the treatment of addictive
disorders: left or right stimulation?
There is very little information available from empirical studies to
help guide the selection of left or right-sided targets for neuromodu-
lation approaches in SUD. Most studies with rTMS have applied excit-
ability enhancing rTMS to the left DLPFC (following the pathway that
was forged by depression researchers). In alcohol research, however,
there has been a unique emphasis on stimulating the right DLPFC. In a
previous meta-analysis, no laterality effect could be found for either
right or left DLPFC stimulation, although there was a trend favoring
right-sided DLPFC rTMS (Enokibara et al., 2016; Jansen et al., 2013).
Recent reviews on the cognitive effects of tES/rTMS in addiction in-
dicate positive effects of both right-sided and left-sided DLPFC stimu-
lation (Naish et al., 2018; Schluter et al., 2018). Both left- and right-
sided stimulation have been shown to enable positive effects on cog-
nition and on craving in addictive disorders, these effects may be due to
non-focal effects of rTMS. Indeed, lateralized rTMS has been shown to
change bilateral brain activation patterns, for instance by activation of
monosynaptic afferents in the contralateral hemisphere (Hanlon et al.,
2013) and influencing bilateral resting-state functional connectivity of
frontostriatal circuits (Schluter et al., 2017). Thus, the question on la-
terality in the treatment of addictive disorders should be put in a wider
perspective, and be approached from a network perspective, where not
only laterality, but also the target location is relevant.
8. tES/TMS dosage in the treatment of SUDs
Stimulation parameters, such as duration, number of stimulation
sessions, stimulation frequency, intensity, target brain region, and in-
terval between treatments, should be investigated to define the dose
response of tES/TMS techniques. Few of these parameters have been
systematically investigated for addiction treatment. The majority of
brain stimulation studies have adopted protocols that modulate cortical
excitability of key brain areas for addiction, such as DLPFC, demon-
strating the potential efficacy in reducing drug craving and addictive-
related behaviors (Li et al., 2013a; Politi et al., 2008; Rapinesi et al.,
2016; Terraneo et al., 2016). Acute multiple sessions of tDCS stimula-
tion protocols, typically related to facilitative effects on cortical excit-
ability (Nitsche and Paulus, 2000; Paulus, 2003), have been associated
with a reduction of spontaneous (Batista et al., 2015; Klauss et al.,
2018b), and cue-induced craving (Boggio et al., 2009; Fregni et al.,
2008; Gorelick et al., 2014) when applied over the prefrontal cortex.
However, there was no effect on spontaneous craving when stimulation
sessions were extended (Klauss et al., 2018a). Similarly, rTMS protocols
at high frequency (5–25 Hz) have typically been used to excite cortical
neurons and elicit LTP-like effects. These methods have been used to
reduce spontaneous and cue-induced craving. There are limited avail-
able studies with direct comparisons to date. Evidence from depression
rTMS studies suggests that longer treatment duration and/or higher
number of rTMS sessions could contribute to faster clinical improve-
ment and better outcomes (Schulze et al., 2018). Future studies should
focus on two main areas: (1) the personalization of the tES/TMS
treatment, and (2) optimization of stimulation parameters, electrodes/
coil size and shape, duration, and number of stimulations.
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9. Preclinical and Pharmacologic insight into the mechanism of
tES/TMS as a tool to decrease drug consumption
Preclinical models have certainly disentangled some of the cellular
and molecular mechanisms by which tES/TMS exert their neurophy-
siological effects, as well as effects of multiple stimulation sessions on
drug-related behaviors (Levy et al., 2007). As noted above (e.g. Chen
et al., 2013; Levy et al., 2007), tES/TMS induce effects at a cellular level
through different mechanisms including the modulation of glutama-
tergic receptors (Gersner et al., 2011) and neuronal excitability eliciting
prolonged, offline after-effects similar to LTP and LTD (Cirillo et al.,
2017; Diana et al., 2017; Nitsche and Paulus, 2000; Paulus, 2003).
Seminal preclinical studies have extensively demonstrated that tES/
TMS induced-LTP/LTD are strictly dependent on NMDA and AMPA
receptor signalling (Cirillo et al., 2017; Diana et al., 2017) within glu-
tamatergic synapses within addiction related brain regions (Argilli
et al., 2008; Diana et al., 2017; Good et al., 2011).
The dependence on glutamatergic activity is supported by the sup-
pression of tDCS induced effects on the primary motor cortex after
NMDA-receptor blockade in humans (Liebetanz et al., 2002; Nitsche
et al., 2003a). In addition to glutamatergic signalling, dopaminergic
transmission is also likely to play a significant role in shaping some of
the TMS-induced effects (Diana, 2011; Strafella et al., 2001). tES/TMS
techniques could also exert their effects modulating the expression of
neurotrophic factors, such as BDNF, an active regulator of synaptic
plasticity, within cortical and subcortical areas (Cirillo et al., 2017;
Custodio et al., 2018). More recently, non-synaptic events have been
suggested as mediators of tES/TMS long-term effects, including plasti-
city-related gene expression, and neurogenesis (Spagnolo and Goldman,
2017; Strube et al., 2015; Zhang et al., 2007). Whether these me-
chanisms are involved in tES/TMS mediated effects in SUDs remains to
be explored.
Animal models provide a powerful tool to map brain activation
patterns after brain stimulation. The few neuroimaging studies avail-
able have suggested that tES/TMS induce neuronal activation both in
cortical and subcortical areas (Hanlon et al., 2013; Moore et al., 2016;
Uhlirova et al., 2016). Nevertheless, it is clear that understanding the
effects of tES/TMS by using animal models is problematic due to
technical limitations and different gyral patterns. Coils, electrode sizes,
and stimulation power represent major issues preventing a direct
comparison of specificity, accuracy, current density and electro-
magnetic field between human and animal studies (Gorelick et al.,
2014; Jackson et al., 2016). Similarly, interspecies differences in
anatomy, receptor, and neurotransmitters distributions should be taken
into account when assessing tES/TMS neurobiological effects. Technical
advances in preclinical studies for tES/TMS are needed in order to in-
crease the focality of stimulation in specific brain areas. The large
protocol variability and lack of standardization at present are detri-
mental and could contribute to the conflicting results reported in the
literature. Therefore, future research should focus on the optimization
of stimulation targets and stimulation parameters such as electrodes/
coil size and shape, duration, and number of stimulation sessions. In-
teractions between brain states (e.g. anesthesia in animals) and stimu-
lation parameters should be further studied in the context of addiction
(e.g., being abstinent or using cocaine will also likely impact the effects
of tES/TMS).
10. Biomarkers for treatment selection and monitoring
As with other neuropsychiatric disorders, there are currently no
clinically useful biomarkers (a measurable indicator of some biological
state or condition) for SUD. Absent such markers, it is impossible to
predict an individual’s vulnerability to addiction, the severity of an
individual’s current level of dependence, treatment effectiveness, or
risk of relapse. A poor understanding of the addicted human brain and
the complex actions of a drug on, and neuroplastic consequences to,
various neural circuits and neurobiological mechanisms, contribute to
the failure in developing more efficacious treatments as the field mostly
relies on a symptom checklists and peripheral markers of exposure (e.g.,
urine drug screen). To move forward in this quest, many believe that a
more proximal, brain-based measure of dependence is required.
Furthermore, the delineation of potential subtypes of addiction, ana-
logous to what was recently described in treating depression (Drysdale
et al., 2017), may result in specialized treatments for unique en-
dophenotypic subtypes.
Emerging evidence suggests that persistent drug use leads to a
dysregulation of multiple cognitive constructs subserved by multiple
neural circuits, networks, and neurotransmitter systems. As such, to
effectively diagnose and treat individuals suffering from SUDs, rather
than concentrating on any given brain region or transmitter as currently
pursued in most medication discovery, a better understanding of how
abused drugs affect the topological organization of brain connectivity
networks may have greater strategic importance (Steele et al., 2019). A
large-scale network measure of connectivity such as Participation
Coefficient or Degree, measured noninvasively with fMRI and/or EEG
from either (or both) resting-state and task-based connectivity measures
reflects the overall functional properties of the brain and may provide a
useful heuristic to explore the efficacy of SUD diagnosis and treatment
interventions.
The trajectory of SUD development from impulsive to compulsive
use is thought to be reflected in changes in various cognitive constructs
and their underlying networks, including reward processing (Haber and
Knutson, 2010), salience detection (SN; Seeley et al., 2007), executive
control (ECN; Seeley et al., 2007), and internal ruminations (default
mode network; DMN; Raichle, 2015). Moreover, SUD is not a static
disease but rather is manifest by cycling between phases, including
binge/intoxication (i.e. reward seeking), abstinence induced with-
drawal (negative affect) and drug craving brain circuits and networks
(For review, see; Koob and Volkow, 2016; Spronk et al., 2013; Steele
et al., 2018a). The hypothesis of an imbalance between drive state and
reward processing (so called ‘go-circuits’) and executive control (‘stop-
circuits’) processes (Bechara, 2005; Bickel et al., 2007; Childress et al.,
1999; Goldstein and Volkow, 2011; Hu et al., 2015; Volkow et al.,
2016) is a manifestation of such dysregulation and has shown promise
as a predictor of drug-related treatment outcomes (Adinoff et al., 2015;
McHugh et al., 2017; Steele et al., 2014; 2018b).
Most measures of large-scale networks implement MRI based mea-
sures, but EEG measures of large-scale networks via phase synchrony
holds tremendous potential due to its exquisite temporal resolution
(e.g., Aviyente et al., 2017; Watts et al., 2018). Event-related potentials
(ERPs) assessing cognitive functions have also successfully predicted
SUD treatment outcomes (Fink et al., 2016; Marhe et al., 2013;
Nakamura-Palacios et al., 2016; Steele et al., 2014). Biomarker devel-
opment incorporating multimodal measures, rather than a single
modality, and taking advantage of both the high spatial resolution of
fMRI and high temporal resolution of EEG is likely to provide a more
complete picture of both the cognitive functions and the underlying
mechanisms dysregulated in SUD. Identification of biomarkers for both
risk and protective factors and targets for treatment will likely uncover
a proximal, brain-based measure of dependence essential for in-
dividualized medicine and curbing the significant societal impact of
SUDs (Yavari et al., 2017).
Non-invasive brain stimulation has shown promise by targeting
networks known to be dysregulated in SUDs (For review: Diana et al.,
2017). In the quest toward individualized medicine, rich datasets that
include several imaging modalities may help fractionate the SUD phe-
notype and identify the most appropriate treatment type, ‘dosage’ and
duration for each individual (c.f., Drysdale et al., 2017). Neuromodu-
lation interventions with focal manipulation of specific dysregulated
networks associated with an individual’s SUD subtype (and potential
comorbidity with other neuropsychiatric disorders) may provide a un-
ique tool to target those networks most compromised in the individual.
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11. Quality standards for designing and reporting clinical
research using tES/TMS
11.1. Pre-registration of clinical trials and responsible reporting of “Big
Data” projects
Good clinical practice states that all clinical trials should be pre-
registered before a study is initiated (Moher et al., 2001). In fact,
funding agencies such as the NIH require that a trial must be previously
registered when submitting a grant request; the International Com-
mittee of Medical Journal Editors (ICMJE) ("ICMJE recommendations,"
Accessed 27 Nov 2018) also requires, by policy, that the trial should
only be considered for publication if it was registered at or before the
time of the first subject enrollment. The ICMJE defines a clinical trial as
any research project that prospectively assigns people or a group of
people to an intervention, with or without concurrent comparison or
control groups, to study the relationship between a health-related in-
tervention and a health outcome. Health-related interventions are those
used to modify a biomedical or health-related outcome; examples in-
clude drugs, surgical procedures, devices, behavioral treatments, edu-
cational programs, dietary interventions, quality improvement inter-
ventions, and process-of-care changes. Health outcomes are any
biomedical or health-related measures obtained in patients or partici-
pants, including pharmacokinetic measures and adverse events. Ac-
cording to the NIH, a clinical trial is defined as studies (1) involving
human participants; (2) in which participants are assigned pro-
spectively to an intervention and the effects of this intervention are
being assessed; (3) the effects are being assessed by a health-related
biomedical or behavioral outcome. ClinicalTrials.gov or the WHO In-
ternational Clinical Trials Registry Platform (ICTRP) are available for
this registration process.
While we encourage all researchers with a traditional clinical trial
to pre-register their studies, we simultaneously acknowledge that the
NIH’s momentum towards data sharing and posting of raw data on
biorepositories will provide a wealth of information that may benefit
brain stimulation target identification studies in the future. In the field
of depression, for example, Drysdale and colleagues recently published
a highly influential article in which they aggregated over 1000 beha-
vioral and resting state fMRI datasets that had been collected from
patients with major depressive disorder. Through machine learning
algorithms they demonstrated that there were 4 prominent “biotypes”
(each containing a set of behavioral and brain imaging features) of
individuals with depression and that individuals with disrupted activity
in the dorsal medial prefrontal cortex happened to be the ones that
responded best to rTMS at the dorsal medial prefrontal cortex (Drysdale
et al., 2017). While a prospective study is still warranted, this in-
vestigation is an elegant demonstration of the manner in which big,
shared data can be a common resource to the field. While this is not
explicitly a clinical trial it has unique value. It is undeniable that similar
studies will likely be attempted in SUD research. In the spirit of trans-
parency, however, we encourage researchers doing this type of data-
driven research to report their findings in a traditional publication or on
a public database so that the research community is made aware of the
results. By increasing the transparency of research and encouraging
individuals to publish outcomes which are both consistent and incon-
sistent with their original hypotheses, we will hopefully help the field
move forward in a more efficient manner.
11.2. Outcome measures/Phases of clinical trials
Outcome measures should be defined a priori, as well as the in-
ferential statistical methods that will be used for the analysis of this
data. Most recent clinical trials on tES/TMS for SUDs are Phase-II trials
(or feasibility/preliminary trials). It is worth discussing that most of
them evaluate clinical endpoints, such as craving assessment, substance
consumption, and relapse rates (Coles et al., 2018). These outcomes are
likely highly clinically relevant, but are likely not as illuminating re-
garding the biological mechanism of observed effects compared to
studies which are able to measure changes in systemic physiology or
neurobiology. Studies that are designed with electrophysiological
techniques or functional imaging as primary outcomes (Li et al., 2013b;
Pripfl et al., 2014) shed light on how stimulation techniques may
modulate brain activity to improve symptoms such as craving assess-
ment, substance consumption, and relapse rates. While we realize that
these techniques are often very expensive and not available to labora-
tories in developing nations (in which SUDs may be just as prevalent as
in nations with ready access to these techniques), we encourage in-
vestigators to collaborate across borders and strive to include a bio-
marker of treatment efficacy in their experimental design. These studies
can also provide important data on mechanistic effects of stimulation
on addiction and withdrawal to test and improve existing protocols, as
well as to design novel interventions. In this context, the aims of the
investigation need to be well defined and surrogate or clinical outcomes
need to be pre-specified.
11.3. Sample size calculation and power/effect size – target engagement
studies versus clinical efficacy studies
In 2015 the National Institute of Mental Health introduced a new
experimental medicine initiative that provided a framework for in-
novative treatment development. It is now the backbone for many NIH-
sponsored neuromodulation treatment grants (Insel, 2015; Krystal
et al., 2018). Briefly, the initiative introduced a concept of early “target
engagement” studies, which are designed to demonstrate that an in-
tervention can modulate a pre-specified biological or behavioral target.
These studies are then followed by a longer period of “clinical efficacy”
evaluation. Although this language and framework is not yet required
at all NIH institutes, we encourage individuals in the SUD field to use
this framework for their studies.
With this framework in mind, careful planning should be under-
taken when calculating sample size as this population can be challen-
ging when considering recruitment and adherence. In particular, clin-
ical efficacy studies with multiple-session stimulation protocols and
long-term follow-up periods can be problematic, with drop-out rates as
high as 89% following 6 months of follow-up (Ceccanti et al., 2015).
The researcher must also consider that single-session target engagement
studies usually do not have problems with adherence, but effect sizes
are often smaller and less meaningful when assessing clinical impact in
longer-term studies. A recent review of brain stimulation methods to
treat SUDs (Coles et al., 2018) showed that the effect-size of tDCS can
vary from Cohen’s d 0.1 to 4.45, depending on the number of stimu-
lation sessions and the substance of abuse, while the effect-size of rTMS
varies from Cohen’s d 0.05 to 4.42. Therefore, the researcher must find
the balance between two extremes: a study with a large sample size and
multiple sessions can become unfeasible due to drop-outs, while a small
sample study and insufficient sessions can easily be underpowered. The
investigator should generate realistic estimates of the effect size and run
different scenarios for power calculation (sensitivity analysis).
11.4. Randomization and blinding
Randomization and allocation concealment are important in the
development and design of clinical trials, as blinding protects the in-
ternal validity of the study. Although balancing of covariates is possible
using different techniques, such as several types of regression analyses,
it is necessary to first know these covariates and then correctly collect
this data. Randomization, on the other hand, allows not only for bal-
ancing of known covariates, but also for unknown ones if the sample
size is large enough. In addition, “block randomization,” can help with
avoiding imbalance of known participant characteristics (e.g. sex)
across conditions.
Blinding has been an important element of debate in the field of
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tES/TMS, as it depends not only on the technique used (e.g., TMS vs.
tDCS) but also on the parameters of stimulation. For instance, a long-
itudinal trial with parallel design and multiple sessions of tDCS is
capable of providing blinding in the same way as a placebo drug
(Brunoni et al., 2013). Cross-over designs should be avoided especially
when stimulation intensity is equal to or greater than 2mA due to the
risk of unblinding (O’Connell et al., 2012). Papers should not only re-
port blinding procedures, but also blinding-success rates (see Section
2.5) (Gorelick et al., 2014). Importantly, success of blinding procedures
should be measured and reported both for participants and study per-
sonnel in double-blind studies.
Strategies to mimic the skin sensation of tES/TMS should be pur-
sued. Skin-redness has been more often reported for active than sham-
tDCS, but that observation was not correlated with prediction of the
treatment effects (Brunoni et al., 2014). Furthermore, pre-treating the
scalp where the tDCS electrodes will be placed with topical anesthetic
solutions has been attempted. Non-steroidal anti-inflammatory drugs
such as ketoprofen can reduce stimulation-induced erythema (Guarienti
et al., 2015) and topical lidocaine can reduce the overall skin sensation
related to tDCS stimulation. However, these agents are not advisable
since there are concerns about systemic absorption from the skin. Ob-
jective outcomes (e.g., biomarkers, neurobiologic indicators) that are
not as vulnerable to placebo effects are an option. In addition, a run-in
phase to exclude high placebo responders can be used to reduce placebo
effect (Fregni et al., 2010). A recent systematic review and meta-ana-
lysis found that sham tES (a-tDCS, c-tDCS, tACS, tRNS and tPCS) does
not result in statistically significant differences in corticospinal excit-
ability (Dissanayaka et al., 2018), meaning that control groups invol-
ving sham procedures are reliable from a neurophysiological standpoint
in tES studies.
11.5. Reporting clinical context
Clinical characteristics of the sample can affect results of studies and
therefore should be considered and reported carefully. As populations
with SUDs are highly variable, it is important to report enough details
of the clinical characteristics in order to determine generalizability.
Substance use history as well as inclusion and exclusion criteria, should
be clearly defined. One future research modification is to enroll subjects
based on the specific behavior rather than signs and symptoms defining
SUD. An effort towards this end is to use the Research Domain Criteria
(RDoC) (Insel et al., 2010) for recruitment. For instance, a study may
include subjects with “drug craving disorder” that includes alcohol
craving, smoking craving, and methamphetamine craving, in order to
target a specific neural circuit associated with craving behavior rather
than a specific drug. The RDoC initiative, launched by the National
Institute of Mental Health can play an important role in this process,
changing how researchers currently design mental disorders trials, in-
cluding addiction.
It is also important to have a good characterization of the study
population for comparison purposes and meta-analyses. Clinical trials
are usually designed based on relevant preliminary data and often cite
related systematic reviews to justify the new study. Reliable inter-
pretation of results of clinical trials requires a discussion in the context
of findings from similar research such as up-to-date systematic reviews.
Therefore, studies should reference the preliminary data in order to
build knowledge based on tES/TMS (Clarke et al., 2007).
11.6. Reporting tES specifications
tES specifications must be based on biological reasoning with a
predefined hypothesis on how these interventions will affect addiction.
Reproducibility of the results is paramount and there must be a clear
description of the protocol used for the interventions (Brunoni et al.,
2012). Montages with anode and cathode positions (including number
of respective electrodes) (Nasseri et al., 2015), how this montage was
determined (measurements, neuro-navigation), size and shape of elec-
trodes (rectangular, circular or EEG type), current intensity, duration,
number of sessions and interval between sessions (Thibaut et al., 2017)
are extremely important parameters that need to be made explicit
(Pinto et al., 2018). For tACS, a particularly vexing problem for the field
has been the confusion between peak-to-peak and true (baseline-to-
peak) amplitude. Detailed definitions of waveform parameters, ideally
combined with a plot of the waveform, are recommended. Allowed and
prohibited concomitant interventions should be clearly defined (Paulus,
2011). Similarly, the duration of active stimulation and the process for
ramping up and down the stimulation used in sham studies should be
clearly defined.
11.7. Reporting TMS specifications
TMS can be used for stimulation or neurophysiological assessment.
For stimulation, specifications must also be based on a predefined hy-
pothesis, with clear definition of location; coil shape (H-coil, figure-8
coil) (Coles et al., 2018); frequency (high vs low-frequency stimulation
and/or patterned stimulation, if present); number of pulses (and train of
pulses in case of high-frequency); duration of the stimulation session;
intensity (if defined as a percentage of the motor threshold or a per-
centage of the output of the machine); and number of sessions (Schluter
et al., 2018). It should be clearly defined how the target location was
found and whether or not neuronavigation was used. Training of TMS
administrators (staff administering interventions) should be specified
(either as referenced to a protocol or using the supplementary data).
Researchers carrying out TMS protocols should be rigorously trained in
the technique to ensure the quality of the technical procedures, guar-
anteeing subject safety and care, and maximizing the possible benefits
for patients (Lefaucheur et al., 2014). For TMS assessments, cortical
excitability can be measured by single or paired-pulsed techniques.
Specifications must include a detailed description of how measurements
were done, such as: motor evoked potential (MEP); resting motor
threshold (MT); short-interval intracortical inhibition (SICI) and in-
tracortical facilitation (ICF). Blinding procedures and methods should
be clearly defined for TMS studies (sham coil, coil tilted, metal plate
under coil) (Gorelick et al., 2014).
12. Safety
The safety of tES and TMS has been exhaustively reviewed, in-
cluding some consideration of use in the treatment of addiction. TMS
safety guidelines are largely based around minimizing risk of seizures
(Rossi et al., 2009). There is currently no direct evidence for increased
risk of serious or non-serious adverse events from TMS or tES in the
treatment of addiction that are casually linked to stimulation. Further,
there is no evidence that standard TMS safety guidelines need to be
specifically adjusted in addiction treatment. Nonetheless, increased
vigilance is always warranted when theoretical concerns exist or in
specific patient subgroups with limited prior data. Any factor that in-
dependently increases the risk of a seizure (e.g. cocaine use, alcohol
withdrawal, benzodiazepine/barbiturate use/withdrawal in opioid use,
tramadol use, bupropion in nicotine treatment) can, in theory, increase
brain sensitivity to TMS induced seizures.
Similarly, there is no evidence that best practices for tES research
(Antal et al., 2017; Bikson et al., 2016, 2018b; Woods et al., 2016b)
need to be adjusted in addiction treatment. tES is not associated with
severe adverse events, however, skin irritation can be produced when
standard protocols are not followed (Bikson et al., 2016). Any risk
factors for tES/TMS that applies to the general population (e.g. pre-
sence of implants, skull defects) would similarly apply in addiction
treatment.
For investigational treatments, risk/benefit analysis is always spe-
cific to each human trial along with any associated regulatory restric-
tions. In order to evaluate if there is eventually a need to propose
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specific safety TMS or tES guidelines for addiction treatment, studies
should carefully report their methods, safety monitoring measures, and
side effects assessments. For instance, patient’s selection criteria (e.g.,
use status such as if they are recently abstinent and for how long or
current user) will provide information on potential status or sub-groups
that may be more hazardous to deliver TMS or tES. Similarly, assess-
ment of adverse events specific to addiction treatment may be included
(e.g., craving level) which will inform on whether these should become
part of safety TMS or tES guidelines. In regards to safety monitoring, if
there is increased risk, one should consider in adding safety monitoring
measures (e.g. urinary samples, blood alcohol levels) to identify if a
patient is currently using a substance and potentially not reporting the
substance use. Finally, there is great interest in treating patients with
addiction as early as possible in their disorders. Thus, safety guidelines
in regards to teenagers or children should be carefully respected when
delivering TMS or tES in younger populations with addiction.
13. Advancements in tES/TMS technologies
Non-invasive brain stimulation modulates neuronal activity through
synergistic interaction with endogenous activity and thus the response
to stimulation is state-dependent (Alagapan et al., 2016; Schmidt et al.,
2014). The response to stimulation varies from person to person and
from moment to moment. Likely, this explains the substantial hetero-
geneity of findings in this field. One promising way to address this
challenge is to refine, adapt, and individualize stimulation such that the
applied perturbation is modulated (ideally in real-time) to maximize
the desired effect on neuronal network dynamics (Thut et al., 2017).
Examples of this feedback approach includes stimulation at specific
phases of an ongoing oscillation, stimulation in response to the detec-
tion of a specific waveform in the EEG, and stimulation as a function of
a non-neuronal physiological variable.
These new approaches bring a new set of challenges for research
studies. First, feedback control requires measurement of brain activity
combined with application of stimulation. However, since both re-
cording and stimulation are based on electromagnetic fields, tracking
brain activity during stimulation is difficult due to interference leading
to stimulation artifacts that are orders of magnitude larger than the
recorded brain signals. New algorithms for stimulation artifact removal
and stimulation approaches that do not suffer from this cross-con-
tamination are under active development. In addition, there are un-
resolved questions about how to choose the appropriate control con-
ditions and how to analyze responses when a research participant has
received a unique stimulation pattern that depended on ongoing ac-
tivity fluctuations. In addition, development of the next generation non-
invasive stimulation technology includes efforts to deliver higher field
strength with higher spatial precision to deeper brain structures
(Grossman et al., 2017; Vöröslakos et al., 2018). This can lead to au-
tomated closed loop stimulation, on the condition that neural correlates
are developed that represent the craving or other symptoms one at-
tempts to treat.
14. Multisite RCTs for addiction medicine: hopes and challenges
A comprehensive literature search was conducted on PubMed
(without time limits). We used similar terms to those presented in
Section 2, but with the addition of ‘multisite’ and its derivates (e.g.,
‘multicenter, ‘multi-site’, “multi-site”, etc.). This search did not return
any articles, and to the best of our knowledge there are no currently
published multisite RCTs that used neuromodulation for the treatment
of addiction. However, several such studies are registered at
ClinicalTrials.gov, all conducted in adults (18–22 to 65–70 years old
participants) from both sexes.
The most advanced one (NCT02126124; estimated to complete re-
cruitment on February 2019) is evaluating deep TMS (dTMS) as an aid
to smoking cessation based on a previous double blind sham-controlled
study (Dinur-Klein et al., 2014b). In this study, a total of 224 partici-
pants in 18 sites received either sham or real stimulation (10 Hz, 120%
RMT, 1800 pulses per daily session) over the prefrontal and insular
cortices for 3 weeks, with maintenance once a week for an additional 3
weeks and a follow-up after 4 months. The primary objective of the
study is to compare the four-week continuous quit rate between the
active and sham treatment groups. Brain imaging data and behavioral
assessments are collected before TMS, and after 10 days of TMS, 1
month follow up, and 2 months follow up.
In another study (NCT03576781; estimated to end on December
2019), 78 opioid dependent individuals and healthy controls are ran-
domized to receive either one placebo-like TMS treatment, or one of
two real TMS treatments aimed to increase activity in the DLPFC with
iTBS (600 pulses, 110% RMT) or decrease activity in the MPFC with
cTBS (600 pulses, 110% RMT). The study measures changes in pain
(using MRI-based thermal pain paradigm) and craving, and the results
will be used to design a larger clinical trial of rTMS as an innovative,
new treatment option for pain in opioid dependent individuals.
Finally, another study (NCT03333460; estimated to end on
December 2020) evaluates whether rTMS can reduce cocaine craving
and use, and affect mood, behavioral, and cognitive alterations asso-
ciated with prolonged cocaine use. In this study, a total of 80 partici-
pants receive either sham or real rTMS (15 Hz, 100% RMT) over the left
DLPFC for two weeks (twice a day), with a maintenance intervention
(twice a week for 3 months) and a follow-up of additional 3 months.
The primary objective of the study is to compare changes to cocaine
craving and consumption, as indicated by self-reports and urine drug
screen, and it also includes Pre- and Post-treatment fMRI scans while
drug-related images are presented.
The challenges of designing and conducting multisite neuromodu-
lation studies for addiction treatment are not fundamentally different
from those conducted for depression (e.g., Levkovitz et al., 2015;
O’Reardon et al., 2007) or of addiction treatment studies in which other
interventions (e.g. pharmacotherapies) have been used (e.g., Falk et al.,
2018). The challenge of bringing in the participants every day for
treatment (rather than taking a medication at home and coming only
for evaluations and follow-ups) is greater, and therefore only subjects
highly motivated to adhere to the study should be recruited. Home use
tES devices might be a solution for this limitation (Shaw et al., 2017).
Clearly, large controlled multicenter studies that allow validation and
generalization of positive preliminary studies are still lacking in this
field to establish neuromodulation as a validated tool in the treatment
of addiction.
Conclusion
The overarching goal of INTAM is to determine the extent to which
tES/TMS will improve the degree and extent of recovery from SUDs.
Research to date has tested the effect of tES/TMS on clinical outcomes
(e.g., substance use) as well as established mechanisms of change (e.g.,
craving). Despite these efforts, consensus has been difficult to de-
termine due to the variability in methodology across tES/TMS studies.
Moving forward, the critical mass of expertise through INTAM and
utilization of a shared matrix of research questions and protocols will
maximize the likelihood of recruiting large clinical cohorts that reflect
the heterogeneity of addiction, further facilitating fully powered sta-
tistical tests of the effects of tES/TMS on clinical outcomes and me-
chanisms of change. A shared matrix of research questions and outcome
measures for the biomarkers, mechanisms and clinical outcomes of
addiction will form the basis of INTAM. In this context, it will also be
critical to define the clinical population (e.g., substance, disorder se-
verity, age, comorbidities) and treatment setting (e.g., detoxification,
relapse prevention).
Pre-registration of study protocols and primary and secondary
outcomes is encouraged to promote transparency. Shared protocols will
enable higher rigor and reproducibility. Protocols should ideally
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contain (1) a detailed description of materials and equipment, (2) step-
by-step administration instructions with accompanying video examples,
where appropriate, (3) information on troubleshooting strategies, and
(4) guides for data processing, analysis, and interpretation. These pro-
tocols could then be used to establish multicenter trials. Finally, the use
of an online data and registration platform will facilitate comparative
and integrative analysis.
The establishment of shared research questions, protocols and data
repository does not come without its challenges. Both within and across
cultures, there exist different norms and ideas about what constitutes a
clinically significant change. For instance, not all cultures emphasize
‘abstinence only’ in treatment, necessitating the ongoing awareness and
open discussion of these types of assumptions. Further, a risk in prior-
itizing well-established procedures and findings is the reduction in ac-
knowledgment of innovative approaches and newly formed theories.
This is particularly critical for a field in its early stages, such as tES/
TMS for addiction.
Therefore, it will be important for INTAM to balance standardiza-
tion with the embrace of a flexible approach and concentrated effort to
regularly integrate and update novel findings into the shared protocols
and a data repository. Although the role of tES/TMS in future daily
clinical practice in addiction medicine is unclear, we hope this colla-
borative effort will lead the research community to high quality em-
pirical research on these techniques such that clinical efficacy can be
established. Through larger, sham-controlled studies with more uni-
form reporting standards in tES/TMS research, we will be better pre-
pared to deliver something meaningful to our patients. Finally, we ac-
knowledge that SUD is a uniquely intransigent condition which will
likely not be solved by a single brain stimulation intervention. By
performing rigorous studies in tES and TMS however, we will be able to
confidently approach the next frontier of experimental medicine in SUD
– combining targeted brain stimulation with pharmacotherapy and
behavioral management in order to optimize treatment efficacy for a
given individual.
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